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Abstract
Kidney donation after circulatory death (DCD) is a less than ideal option to meet organ shortages. Hypothermic machine perfusion
(HMP) with Belzer solution (BS) improves the viability of DCD kidneys, although the graft clinical course remains critical. Mesenchymal
stromal cells (MSC) promote tissue repair by releasing extracellular vesicles (EV). We evaluated whether delivering MSC-/MSC-derived EV
during HMP protects rat DCD kidneys from ischaemic injury and investigated the underlying pathogenic mechanisms. Warm ischaemic
isolated kidneys were cold-perfused (4 hrs) with BS, BS supplemented with MSC or EV. Renal damage was evaluated by histology and
renal gene expression by microarray analysis, RT-PCR. Malondialdehyde, lactate, LDH, glucose and pyruvate were measured in the efflu-
ent fluid. MSC-/EV-treated kidneys showed significantly less global ischaemic damage. In the MSC/EV groups, there was up-regulation of
three genes encoding enzymes known to improve cell energy metabolism and three genes encoding proteins involved in ion membrane
transport. In the effluent fluid, lactate, LDH, MDA and glucose were significantly lower and pyruvate higher in MSC/EV kidneys as com-
pared with BS, suggesting the larger use of energy substrates by MSC/EV kidneys. The addition of MSC/EV to BS during HMP protects
the kidney from ischaemic injury by preserving the enzymatic machinery essential for cell viability and protects the kidney from reperfu-
sion damage.
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Introduction
The pool of kidneys currently available for transplantation could be
expanded with the procurement of organs from the DCD. Never-
theless, the use of DCD kidneys is limited by a high rate of pri-
mary non function and delayed graft function and acute rejection,
which results in a worse clinical course [1–8]. Ischaemia occur-
ring in DCD kidneys causes metabolism slowdown and the
consumption of ATP and adenosine diphosphate residual pools.
The injury caused by ischaemia is worsened during reperfusion
due to the accumulation of free radicals and reactive oxygen spe-
cies (ROS) [9–14]. HMP with BS improves DCD kidney viability by
providing metabolic sources for ATP generation and glutathione,
which protect against ROS [15–17]; nevertheless, the graft clinical
course remains poor [3–5]. MSC are multipotent cells that abate
immune and inflammatory responses and promote tissue repair
also by releasing EV [18–29]. We have already shown that MSC
injection in a renal transplant model protects the graft by reducing
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ischaemia/reperfusion injury and acute rejection and guides the
cytokine network towards a tolerogenic one [30–33]. The original-
ity of our study resides in a new application of MSC, consisting in
pre-transplant graft perfusion. The core rational behind this appli-
cation is that delivering MSC- or MSC-derived EV (hereafter named
EV) to the isolated kidney, as part of the HMP procedure, prepares
renal cells and the environment to face the incoming injury, rather
than contrasting the assault once it has fired up. Thus, we investi-
gated this novel approach in a rat DCD model and evaluated the
morphological, biochemical and molecular effects of MSC/EV on
perfused kidneys.
Materials and methods
Animals
Fisher F344 (F) rats were used as kidney donors (Charles River, Lecco,
Italy). Transgenic Sprague Dawley (SD) rats expressing Enhanced Green
Fluorescence Protein (EGFP) [34] (Japan Slc, Hamamatsu, Japan) were
used as MSC donors. Rats weighed between 125 and 150 g. Animals
were handled according to the guidelines of the Italian Health Ministry
(n° 339/2016-PR).
MSC expansion and characterization
MSC were isolated from bone marrow of EGFP transgenic SD rats,
expanded in vitro and used at P2/P3 as previously described [35].
EGFP-rat MSC, hereafter referred to as MSC, were characterized for
plastic adhesion, morphology, antigen surface expression of CD49e,
CD90 and CD29 and the absence of CD45 and CD11b (all antibodies
were purchased from BioLegend, San Diego, CA, USA) performed with
a Navios flow cytometer (Beckman Coulter, Milan, Italy) and differentia-
tion capacity [35].
EV isolation and characterization
EV were obtained from supernatants of MSC at 80% confluence, as pre-
viously described [26]. Briefly, MSC were cultured overnight in D-MEM
(Gibco, Life Technologies, Milan, Italy) without foetal calf serum (FCS).
Supernatants were centrifuged at 3,000 9 g for 20 min. to remove cel-
lular debris, and cell-free supernatants were then centrifuged twice at
100,000 9 g for 1 hr at 4°C.
Fluorescent beads ranging in size from 0.1 to 1 lm (Megamix; Bio-
Cytex, Marseille, France) were employed to precisely gate EV. As EV
derived from MSC express surface molecules that are characteristic of
the cells of origin, anti-rat CD49e (as positive marker) and anti-rat
CD45 (as negative marker) (both from BioLegend) were used. The anal-
ysis was performed by direct immunofluorescence with a Navios flow
cytometer (Beckman Coulter), and the data were analysed using Kaluza
software. Moreover, some specific exosomal markers, such as CD63,
CD9 and CD81 (Miltenyi Biotec, Bergisch Gladbach, Germany), were
also analysed, using the Guava easyCyte FlowCytometer (Millipore, Bill-
erica, MA, USA) with InCyte software.
MSC viability
To test whether hypothermia affects MSC activity, after exposition at
4°C for 2 and 4 hrs, cell viability was evaluated with the Trypan blue
exclusion test. Viable cells had a clear cytoplasm, whereas non-viable
cells had a blue cytoplasm. The viability percentage was calcu-
lated = [number of viable cells/ total n. of cells (viable + non-
viable)] 9 100.
In vivo experiments
Using the rat DCD kidney model, rats were anaesthetized using Isoflu-
rane 2–5% (Baxter, Como, Italy). After a midline laparotomy, the left
retroperitoneal renal area was exposed and the lumbar arteries were
isolated and sectioned; subsequently, the renal artery and vein were
isolated. After 20 min. of warm ischaemia obtained by renal artery
clamping, the left nephrectomy was completed with the preservation of
the renal hilum. Kidneys were then perfused with BS (n = 5), or with
BS supplemented with 3 million MSC (n = 5), or BS supplemented with
EV isolated from 3 million MSC (n = 5). Continuous perfusion was per-
formed for 4 hrs at 4°C, and then, the effluent fluid was collected and
stored at 20°C. Kidneys were split into two aliquots, one fixed in
10% formalin for morphological studies and the other frozen in liquid
nitrogen for RT-PCR. For the microarray analysis, we also studied
another group of non-perfused kidneys (n = 5) (NP) obtained after
20 min. of warm ischaemia and preserved in RNA later (Ambion, Aus-
tin, TX, USA).
Renal histopathology
EGFP expression
To track MSC, EGFP renal expression was studied by immunohisto-
chemistry as already described [35]. Briefly, 3-lm-thick sections of
paraffin embedded tissue were collected on poly-L-lysine-coated slides
(Dako, Glostrup, Denmark). These were dewaxed in xylol, passed in a
decreasing series of alcohol and rehydrated with distilled water.
Endogenous peroxidase was blocked with H2O2/methanol 3.7% vol/vol
for 10 min. followed by H2O2. After three washings in PBS, the sec-
tions underwent microwave antigen retrieval, then were exposed over-
night at 4°C to monoclonal mouse anti-green fluorescent protein
antibody IgG1 (Chemicon International, Billerica, MA, USA). After three
washings in PBS, the immunocomplex was visualized with the biotin–
streptavidin–peroxidase complex and 3,3-diaminobenzidine (Dako).
Sections were counterstained with Harris haematoxylin. Negative con-
trols included both omission of the primary Ab and substitution of IgG
for primary antibodies. Kidney sections of SD-EGFP were used as pos-
itive controls. We counted EGFP-positive cells/HPF (9400) in 10 renal
sections per kidney.
Renal morphology
Twenty subserial cross-sections of each kidney were stained with peri-
odic acid–Schiff (PAS) and examined by two investigators in a double-
blind fashion, using an Olympus IX8 microscope connected to a CCD
camera and the software imaging analysis Cell-R.
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Renal damage was evaluated by counting the percentage of
tubules/HPF in at least 10 non-consecutive fields presenting with
the following lesions: tubular epithelial cell flattening, brush border
loss (BBL), bleb formation (BF), tubular necrosis (TN) and tubular
lumen obstruction (TO) [36]. Tubular epithelial cell flattening (TF)
and BBL were classified as mild lesions; BF, TN and TO as severe
lesions.
The global renal damage score, as described by Paller et al. [12],
was obtained by assigning each lesion a different score: TF(1 point),
BBL (1 point), cell membrane BF (2 points), TN (2 points) and TO (2
points). When two or more lesions were present in the same tubule,
the most severe score was assigned.
Biochemical assays
In effluent fluid, malondialdehyde (MDA) amounts were quantified with
the HPLC method using the Chromosystems assay kit (Chromosystems
GmbH, Gr€afelfing, Germany). Glucose, lactate and LDH were quantified
with a Clinical Chemistry Analyser (ARCHITECT, Abbot, Italy), and the
pyruvate concentration was measured by spectrophotometry (Beckman
Coulter). All experiments were quadruplicated.
RNA extraction and RT-PCR in BS, MSC/EV
kidneys
Total RNA was extracted using the TRIzol method. RNA was treated
with DNase from the RNase-Free DNase Set (Qiagen, Hilden, Germany)
and dissolved in nuclease free water. Extracted RNA was tested for
quantity and integrity by spectrophotometric analysis (NanoDrop;
Thermo Scientific, Waltham, MA, USA). A total of 1 lg of RNA per con-
dition was reverse transcribed into cDNA with the 1st Strand cDNA Syn-
thesis Kit for RT-PCR (AMV) (Roche Applied Science, Penzberg,
Germany). cDNA was used to perform the real-time PCR analyses in
96-well optical reaction plates, using ABI prism 5700 (Applied Biosys-
tems, Waltham, MA, USA) and the 5-exonuclease assay (TaqMan tech-
nology) in a 10 ll reaction volume containing TaqMan Universal Master
Mix, optimized concentrations of FAM-labelled probes for B2 m, Idh2,
Ndufs8, Pdhb, Calb1, Slc16a1 and Atp6v0d2 (Applied Biosystems, cata-
logue numbers Hs00187842_m1, Hs00158033_m1, Hs00159597_m1,
Hs00168650_m1, Hs01077197_m1, Hs01560299_m1 and
Hs00403032_m1, respectively). Water replacing the cDNA was included
in the real-time PCR as a control. The results were analysed using a
comparative method, and values normalized to the b2 m expression
and converted into fold change. All experiments were quadruplicated.
Microarray analysis
To infer the transcriptional changes induced by perfusion, in a prelimi-
nary experiment, after warm ischaemia, five non-perfused kidneys (NP)
and five MSC-perfused kidneys (MSC) were stored in RNA later and
processed for microarray gene expression analysis.
RNA was extracted using the RNeasy Mini Kit (Qiagen) according
to the manufacturer’s instructions. RNA quality was assessed using
Bioanalyser (Agilent, Santa Clara, CA, USA) and was quantified using
spectrophotometry (Nanodrop, DE). Total RNA was amplified using
the Agilent Low Input Quick Amp WT labelling kit according to the
manufacturer’s instructions. Briefly, 100 ng of total RNA was used to
synthesize double-stranded cDNA, which was amplified by in vitro
transcription and labelled with cy3-dCTP. Fluorescent dye-labelled
cRNA was hybridized to SurePrint G3 Rat GE 8 9 60K Microarray,
containing probes recognizing about 30,000 transcripts designed on
RefSeq Build 36.2. Hybridization and washing were performed on the
Agilent’s Microarray Platform according to Agilent’s standard proto-
cols. Microarray images were acquired using the Agilent DNA
microarray scanner. Raw gene expression data were generated using
the Agilent feature extraction software and were preprocessed using
the limma package [37]. Briefly, raw data were log2 transformed and
normalized using the function normalize Between Arrays with cyclic
loss normalization. Normalized data were filtered according to the fol-
lowing procedure: for each array, probes were referred to as ‘ex-
pressed’ if they had an intensity signal greater than 10% of the 95th
percentile of the negative control probes, then we filtered out probes
referred to as ‘expressed’ in less than four samples. After filtering,
replicated probes were summarized by calculating their average
expression. Finally, we collapsed genes targeted by multiple probes
using the ‘maxRowVariance’ method implemented in the collapse
Rows function of the WGCNA package [38].
Genes differentially expressed between biological classes were identi-
fied using the linear model approach with the empirical Bayes method
implemented in the limma package. Multiple-testing correction was per-
formed using the Benjamini–Hochberg false discovery rate (FDR). Genes
with an FDR < 0.05 were considered significant.
To identify known biological pathways altered between biological
classes, we ran a gene set enrichment analysis (GSEA) using GSEA
v2.0.13 software [39]. Gene sets retrieved from MSigDB (canonical
pathways, C2.cp.v5.1 collection) were tested for enrichment, and those
with a P-value <0.001 and an FDR < 0.05 were selected as significantly
enriched. GSEA results were visualized using Cytoscape v2.8.3 software
and the Enrichment Map plugin. Core genes were identified by leading
edge analysis of significantly enriched gene sets. All microarray data
were MIAME compliant and were deposited into the NCBI’s GEO data-
base (http://www.ncbi.nmlm.nih.gov/projects/geo/) with accession num-
ber GSE84563.
Statistical analysis
GraphPad Prism software (San Diego, CA, USA) was used for the statis-
tical analyses. Biochemical measures were compared using the Stu-
dent’s unpaired t-test. ANOVA followed by the Newman–Keuls test was
applied to compare continuous variables among more than two groups.
A P < 0.05 was considered statistically significant.
Results
Rat MSC and EV characterization
MSC showed the typical spindle shape morphology and maintained
their capacity to in vitro differentiate into osteoblasts and adipocytes
as confirmed by the presence of mineralization nodules and fat dro-
plets with histological staining, as already described [35]. MSC
resulted positive for CD49e, CD90 and CD29, while they were negative
for CD45 and CD11b (Fig. 1A). EV were CD49e positive and CD45
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negative (Fig. 1B), and expressed some specific exosomal markers,
such as CD63, CD9 and CD81 (Fig. 1C).
Short-term hypothermia marginally affected MSC viability; in fact,
the percentage of viable MSC after exposure at 4°C for 2 and 4 hrs
was 86% and 84%, respectively.
EGFP-MSC homing tracking
In MSC-perfused kidneys, EGFP staining (5–10 cells per section) was
tracked in vessels, tubules and interstitium (Fig. 2). There was no evi-
dence of macro/microvascular engorgement or thrombosis.
Renal ischaemia damage was more severe in
kidneys perfused with BS than MSC or EV
Figure 3 shows renal lesions evaluated in the DCD model. TF
(Panel A) and BBL (Panel B, blue arrow), BF (Panel B, red arrow), TN
and TO (Panel C, white arrow TN and yellow arrow TO). Figure 4A–C
shows representative renal sections of perfused kidneys. The preva-
lence of different types of lesions in BS-, MSC- and EV-perfused kid-
neys is reported in Figure 4D–I.
Tubular epithelial cell flattening was significantly more present in
tubules from MSC-perfused kidneys (43.2%) versus BS (30.7%) and
EV-perfused kidneys (21.3%) (Fig. 4D), BBL was more pronounced
in MSC (40.9%) and BS (45.0%) compared to EV (27.7%) kidneys
(Fig. 4E). Severe lesions were more evident in BS than in MSC and
EV kidneys: in BS, 39.0% of tubules presented with blebs versus 5%
in MSC and 7.0% in EV (Fig. 4F), TN was more evident in BS (41.0%)
than in MSC (0%) and EV (5.0%) (Fig. 4G) and lumen obstruction
was significantly present in BS (29.0%) and almost absent in MSC
(0%) and EV (7.0%) (Fig. 4H). The global renal damage score was
Fig. 1 Rat MSC and EV cytofluorimetric characterization. Panel A. Immunophenotype of one representative expanded rat EGFP-MSC culture. Repre-
sentative dot plot of MSC gated by physical parameters and histograms of surface marker expression (grey ispots) and isotypic controls (black
ispots). Rat MSC are negative for CD11b and CD45 and positive for CD90, CD49e and CD29. Panel B. Representative dot plot of EV gated by dimen-
sion parameters, using 1-lm calibration beads. Representative histograms of surface marker expression (grey ispots) and isotypic controls (black
ispots). Rat EV were positive for CD49e and negative for CD45. Panel C. Representative histograms of specific rat EV markers (continuous line) and
isotypic controls (broken line). Rat EV were positive for CD63, CD81 and CD9.
Fig. 2 Homing tracking of rat EGFP-MSC. Representative renal section
of MSC-perfused kidneys. EGFP immunohistochemistry showing tubular
and vascular localization of MSC. Magnification 9400.
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significantly more severe in kidneys perfused with BS (55.9%) than
MSC (31.1%) and EV (23.5%) (Fig. 4I).
Cell energy metabolism and membrane transport
genes were up-regulated in MSC-/EV-perfused
kidneys
After hybridization onto the microarray, one of the MSC samples
resulted as poor quality and was discarded. Therefore, the com-
parison was made between five NP samples and four MSC sam-
ples. Differential expression analysis between the two biological
classes revealed only two genes that were significantly up-modu-
lated (fold change >1.5 and FDR < 0.05) in MSC-treated kidneys:
Tmem52b, encoding a transmembrane protein, and Calb1 that
encodes a calcium binding protein (Fig. 5A). No significantly
down-regulated genes were found. To interpret the biology under-
lying and identify subtle differences commonly present in gene
sets, we applied GSEA for the identification of perturbed biological
processes after MSC perfusion. We identified 20 gene sets that
were significantly enriched in MSC-perfused samples; of these, 13
were related to molecular transport, respiratory electron transport,
the citric acid cycle and some of them overlapped these categories
(Fig. 5B) (see Fig. S1 for the complete list of significantly enriched
gene sets).
We focused our attention on metabolic processes and the identifi-
cation of core genes driving the enrichment of these gene sets. We
performed a cutting edge analysis and selected those occurring in at
least two gene sets. The expression of these genes in MSC-perfused
and NP samples is shown in Figure 5C. We selected five genes for
further analyses, those with a key role in energetic metabolism and
membrane transport.
From the microarray analysis, we selected three genes encoding
proteins that contribute to improved mitochondrial activity, ATP syn-
thesis and BS antioxidant effects (Idh2: isocitrate dehydrogenase 2;
Ndufs8: NADH dehydrogenase Fe-S protein 8; Pdhb: pyruvate dehy-
drogenase beta) and three genes encoding proteins involved in mem-
brane transport and cellular homoeostasis preservation (Calb1:
Calbindin 1; Slc16a1: monocarboxylate transporter 1; Atp6v0d2: vac-
uolar H+-ATPase d2 Subunit).
Idh2, Ndufs8 and Pdhb mRNA expression was
up-regulated in MSC/EV renal tissue, Calb1,
Slc16a1 and Atp6v0d2 mRNA was up-regulated
in EV renal tissue
RT-PCR of selected genes was performed in renal tissues from the
BS, MSC and EV groups (n = 5 for each group). This analysis showed
that mRNA expression of Idh2, Ndufs8 and Pdhb was significantly
higher in kidneys perfused with MSC and EV than in those perfused
only with BS (Fig. 6A–C).
Moreover in EV, but not in MSC-perfused kidneys, we found the
up-regulation of Calb1, Slc16a1 and Atp6v0d2 mRNA in comparison
with BS group (Fig. 6D-F).
Markers of ischaemic damage and glucose were
lower, pyruvate was higher in MSC/EV than BS
effluent fluid
After 4 hrs of perfusion at 4°C with BS alone or in the presence of either
MSC or EV, the effluent fluid was collected and stored at 20°C till the
time of analysis. The markers of disease activity [40], LDH and lactate
and of oxidative stress and lipid peroxidation [41]. MDA were signifi-
cantly higher in effluent fluid of BS kidneys (lactate 5.66  0.99 mg/dl;
LDH 64.75  11.90 mU/ml; MDA 0.41  0.06 mcU/ml) compared to
MSC (lactate 3.12  0.12 mg/dl; LDH 37.67  8.1 mU/ml; MDA
0.23  0.05 mcU/ml) and EV kidneys (lactate 2.51  0.98 mg/dl; LDH
16.33  16.23 mU/ml; MDA 0.12  0.004 mcU/ml) (Fig. 7A–C). Glu-
cose levels in effluent fluid from BS kidneys were significantly higher
(170.8  13.77 mg/dl) than in MSC (132.7  2.80 mg/dl) and EV
(59.0  7.60 mg/dl) (Fig. 7D). Pyruvate levels in MSC
(0.89  0.02 mg/dl) and EV effluent (1.1  0.04 mg/dl) were signifi-
cantly higher than in BS effluent (0.41  0.20 mg/dl) (Fig. 7E).
A B C
Fig. 3 Renal lesions evaluated in the DCD model. Formalin-fixed tissue stained with PAS. Panel A. Tubular epithelial cell flattening (TF). Panel B. Blue
arrow indicates brush border loss (BBL), and red arrow indicates bleb formation (BF). Panel C. Yellow arrow indicates tubular lumen obstruction
(TO) and white arrow tubular necrosis (TN). Magnification 9400.
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Fig. 4 Ischaemic renal damage in BS and MSC-/EV-perfused kidneys. Representative renal sections of kidneys perfused after 20 min. of ischaemia
either with Belzer solution (BS) (panel A), or Belzer solution supplemented with 3 million MSC (MSC) (panel B) or Belzer solution supplemented with
EV derived from 3 million MSC (EV) (panel C). PAS staining, magnification 9200. Panels D-I. Boxplots showing the distribution of renal lesions in
all groups. Box: median, 25–75° percentile; whiskers, 5–95° percentile. Data are the percentage of tubules/HPF in which the lesions were observed.
Panel D. *P < 0.05 versus BS and EV. Panel E. *P < 0.05 versus BS. Panel F. *P < 0.0001 versus BS. Panel G. *P < 0.0001 versus BS. Panel H.
*P < 0.0001 versus BS. Panel I. *P < 0.0001 versus BS. TF: tubular epithelial cell flattening, BBL: brush border loss, BF: bleb formation, TO: tubular
lumen obstruction, TN: tubular necrosis
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Fig. 5Microarray gene analysis. Gene expression profiling of kidneys perfused with MSC (MSC) compared with non-perfused kidneys (NP). Panel A.
Volcano plot of log2 fold changes versus –log10 FDR showing transcriptional differences between MSC-perfused samples and controls. Vertical dashed
lines represent the 1.5-fold change cut-off, and the horizontal dashed line denotes the 0.05 FDR cut-off. Panel B. Enrichment map of significantly
enriched gene sets at P < 0.001 and FDR < 0.05. Nodes represent gene sets connected by an edge when they share common genes. Node size is pro-
portional to the number of genes in the gene set, and edge thickness is proportional to the overlap between gene sets. Red gene sets are enriched in
MSC-perfused samples, blue gene sets in controls. Highly interconnected gene sets are biologically related and were manually annotated into macro-
categories. Panel C. Heatmap showing the expression of core genes, identified by leading edge analysis of metabolic gene sets, in MSC-perfused and
control samples. Only genes shared by at least two gene sets were selected. Vertical bars are colour-coded according to gene set clusters in panel B.
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Discussion
It is known that hypothermic perfusion with BS ameliorates the viabil-
ity of grafts [1]. Here, we report in a rat model of DCD kidney that
pre-conditioning with MSC, and even more with MSC-derived EV,
results in a significant reduction in renal ischaemic injury. During
ischaemia, there is a switch from aerobic to anaerobic metabolism,
which leads to intracellular changes: ATP levels decline, intracellular
calcium and protons increase together with mitochondrial membrane
permeability, ROS rise, and lysosome enzymes are released with
Fig. 6mRNA expression of cell energy metabolism and membrane transport genes validated by RT-PCR in BS, MSC and EV groups. Columns show
gene mRNA expression normalized to beta-actin expression and converted to fold change. Data are means  S.D. The groups are defined in Fig-
ure 4. Panel A. Isocitrate dehydrogenase 2 (Idh2) mRNA expression (°P < 0.005 versus BS; *P < 0.05 versus EV and BS). Panel B. NADH dehydro-
genase (ubiquinone), Fe-S protein 8 (Ndufs8) mRNA expression (°P < 0.005 versus BS; *P < 0.05 versus BS). Panel C. Pyruvate dehydrogenase
beta (Pdhb) mRNA expression (*P < 0.05 versus BS; °P < 0.01 versus BS). Panel D. Calbindin1 (Calb1) mRNA expression (°P < 0.05 versus BS).
Panel E. Monocarboxylate transporter 1 (Slc16a1) mRNA expression (°P < 0.05 versus BS and MSC). Panel F. Vacuolar H + -ATPase d2 Subunit
(Atp6v0d2) mRNA expression (°P < 0.01 versus BS and MSC).
Fig. 7Markers of ischaemic damage and energy substrates in effluent fluid. Columns show levels of lactate (mg/dl), LDH (mU/ml), malondialdehyde
(MDA) (mcU/ml), glucose (mg/dl) and pyruvate (mg/dl) in effluent fluid from each group. Data are means  S.D. The groups are defined in
Figure 4. Panel A. *P < 0.05 versus BS. Panel B. *P < 0.05 versus BS. Panel C. *P < 0.05 versus BS; °P < 0.01 versus MSC. Panel D. *P < 0.05
versus BS. Panel E *P < 0.05 versus BS; °P < 0.005 versus BS.
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consequent cell structure breakage [9–13]. In addition, hypoxia inhi-
bits glucose oxidative phosphorylation; thus, anaerobic glycolysis
remains the only source of ATP production. Conversion of pyruvate
into lactate quickly overloads cells with lactate and protons; hence,
lactate becomes the leading actor in cellular metabolism. Proton
excess disrupts phospholipid membrane integrity, while an ATP
shortage deprives ion transporters of fuel causing intracellular ion
accumulation and cell swelling [42, 43]. All these events result in cel-
lular architecture subversion and morphological changes [44, 45].
Even though in our experimental groups, a heterogeneous pattern of
lesions was observed, the global renal damage score was significantly
lower in MSC/EV as compared with BS kidneys, where a higher per-
centage of severe lesions was observed. The damage progression in
MSC-perfused kidneys was limited to early stages, while EV were the
most effective in stopping the progression of ischaemic injury.
The gene expression array analysis shed light on why MSC/EV
delivery to the isolated organ provides protection for the DCD kidney.
In fact, gene pathways for molecular transport, respiratory electron
transport and the citric acid cycle were significantly up-regulated in
MSC compared to NP. The results obtained comparing MSC with NP
kidneys were studied in BS, MSC and EV kidneys by RT-PCR mRNA
expression of six key genes, whose functions could enhance BS effi-
ciency and improve cell homoeostasis during cold perfusion.
Overall, analyses of the biochemical products in perfused kidney
effluents were in agreement with the histopathological data and sup-
ported by the final effectors of gene pathways up-regulated in MSC/
EV kidneys. In fact, in BS effluent fluid the ischaemic damage marker
levels (LDH, lactate) and MDA, expression of oxidative stress and
lipid peroxidation, were significantly higher than in MSC/EV effluent.
Improved MSC/EV kidney viability was also justified by the effluent
levels of glucose and pyruvate, important intermediates in energy
metabolism. Compared with BS, effluent glucose levels were lower in
MSC/EV kidneys, while pyruvate levels were higher possibly indicat-
ing an increased glucose conversion into pyruvate. On the other hand,
it is known that ischaemia induces persistent pyruvate depletion [42]
and pyruvate administration during ischaemia protects kidneys from
injury;[14, 46, 47] thus, we propose that the higher levels of pyruvate
preserved MSC/EV kidneys through its antioxidant and anti-inflamma-
tory effects [42, 48, 49].
The cell energy metabolism pathways and ion membrane trans-
porters up-regulated in the MSC/EV groups, and their effectors are
reported in Figure 8.
The Idh2 gene encodes for isocitrate dehydrogenase 2, which
generates NADPH, and is indispensable for producing reduced glu-
tathione (GSH), potent antioxidant [50–54]. Thus, we think that Idh2
upregulation in MSC-/EV-perfused kidneys could provide greater
NADPH availability and ensure that glutathione, supplied by BS, ame-
liorates its antioxidant activity. Similarly, the Ndufs8 gene, which
encodes NADH-ubiquinone oxidoreductase, induces a proton flux and
an electrochemical potential across the mitochondrial membrane that
drives ATP synthesis [55–58]. Hence, the greater ubiquinone avail-
ability, together with adenosine provided by BS, may accelerate ATP
synthesis reducing energy depletion. Our hypothesis is supported by
evidence from an ischaemia–reperfusion model where the administra-
tion of reduced ubiquinone improves renal damage, by enhancing
electron transport, preventing ROS generation and increasing ATP
production [59]. The Pdhb gene, encoding pyruvate dehydrogenase
beta, has a key role in ischaemic cell energy metabolism. It is known
that acute kidney ischaemia decreases PDH and pyruvate levels,
increases lactate levels [42] and that pyruvate administration protects
from ischaemic injury [14, 46–49]. As Figure 8 shows, pyruvate is
central to many metabolic pathways: (i) glycolysis, which leads to
pyruvate generation; (ii) pyruvate decarboxylation by PDH, which
leads to acetyl-CoA formation; (iii) pyruvate–lactate conversion; and
(iv) pyruvate decarboxylation during H2O2 scavenging. In MSC/EV
kidneys, we observed upregulation of the Pdhb gene, that potentially
should increase pyruvate to acetyl-CoA conversion resulting in a
decrease of pyruvate levels in effluent fluid. Experimentally, we
observed a pyruvate rise, but this could be explained by the reduction
in LDH levels and pyruvate–lactate conversion, and by the decreased
pyruvate consumption by H2O2-mediated decarboxylation (H2O2 scav-
enging). In fact, MDA levels were lower in treated kidneys. Calb1
encodes calbindin1, a calcium binding protein, that plays a pivotal
role in intracellular calcium regulation and prevents calcium toxicity
[60]. Ca2++ overload causes oxidative stress generating ROS and
induces apoptosis and cell death opening mitochondrial transition
pores [10, 11, 61]. Several studies have already demonstrated the
protective effect of calbindin1 in experimental models of ischaemic
stroke [62], retinal ischaemia [63] and cyclosporine A toxicity in tubu-
lar cells [64]. Slc16a1 encodes for MCT1, an almost ubiquitous pro-
tein whose role is to facilitate L-lactic acid transmembrane
movements. During hypoxia or anoxia, MCT1 exports lactic acid accu-
mulated during anaerobic glycolysis, reducing intracellular acidosis
[43, 65–67]. The protective effect of MCT1 upregulation and conse-
quent lactate export has already been described in myocardial
ischaemia–reperfusion injury [68]. The Atp6v0d2 gene encodes sub-
unit isoforms of H + -ATPase which transports protons across the
cellular membrane; this action is required to reduce intracellular aci-
dosis [69–71]. Interestingly, the last three genes were significantly
up-regulated only in EV-perfused kidneys in agreement with their bet-
ter histopathological preservation.
We hypothesize that the major effectiveness of EV versus MSC
may depend on the prompt availability of MSC mediators contained in
EV. Furthermore, EV were released by MSC, conditioned overnight in
DMEM without FCS; therefore, they were committed to an energy
depletion setting [28]. In vitro studies have shown that the EV incor-
poration rate was accelerated in ATP-depleted tubular cells [28] and
correlated positively with intracellular proton concentration [72]. Fur-
thermore, the release of EV from primary cultures of cytotrophoblast
cells was inversely correlated with oxygen tension. [73] These find-
ings suggest that soluble EV are more promptly available to hypoxic
cells than EV delivered by MSC. Therefore, free EV would oppose the
cascade of reactions sparked by ischaemia in an earlier stage and be
more effective in preventing ischaemic injury. EV contribute to MSC
paracrine action by delivering microRNA, mRNA, long non-coding
RNA and occasionally genomic DNA into target tissues and can bind
target cells through specific receptors and transfer proteins, lipids,
mRNAs and miRNAs [25–28]. Recently, it has been reported that
MSC-derived EV modulate miRNA in renal tubular cells and inhibit
ATP depletion injury [28]. In glycerol [26], cisplatin [25] and
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ischaemia–reperfusion model of acute kidney failure [74], the intra-
venous administration of EV or MSC had the same efficacy on func-
tional and morphological recovery.
In conclusion, we have demonstrated that MSC/EV administration
in addition to BS, normally used in HMP for DCD organs, blocks renal
ischaemic damage at an early stage by preserving the enzymatic
Fig. 8 Schematic representation of cell energy metabolism pathways and ion membrane transporters up-regulated in MSC/EV groups.
10 ª 2017 The Authors.
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machinery essential for cell viability and prepares the kidney for
reperfusion damage. To the best of our knowledge, this is the first
report on new gene pathways by which MSC/EV may act in tissue
protection/repair. Even though the in vivo portion of the study was
limited, for example, the transplantation of treated kidneys was not
performed, we strongly believe that our results should pave the way
for more in depth, in vivo studies; in fact, the future steps of this pro-
ject will be the identification of mediators involved in the better effec-
tiveness of EV and the transplant of kidneys conditioned with MSC
or EV.
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